EGFR TKIs have clearly been clinically efficacious in responsive types of cancers (expressing kinase-activating mutations in EGFR), however, the benefits are often limited to improving the progression free survival (PSF) and quality of life rather than the overall survival (OS) (116–121). The gene discussed is EGFR; the disease is cancer.